Dr Feng, Yibin...2020/02/07 · awarded over 20 million HK$ from 2004-2020. Being an expert in the study of Chinese Materia Medica, Pharmacology and Toxicology of Chinese medicines,

1

Curriculum Vitae in English and Chinese

Dr Feng, Yibin (馮奕斌) Acting Director, Associate Professor

School of Chinese Medicine,

Li Ka Shing Faculty of Medicine,

The University of Hong Kong CONTACT INFORMATION Address: School of Chinese Medicine, The University of Hong Kong

10 Sassoon Road, Pokfulam, Hong Kong

Tel: (852) 3917 6476

Fax: (852) 2872 5476

Email: [email protected]

SPOKEN LANGUAGES

Mandarin, English, Cantonese and Japanese

WRITTEN LANGUAGES

Chinese, English, and Japanese

AREAS OF EXPERTISE

Chinese Materia Medica, Pharmacology and toxicology of Chinese medicines; Cancer, metabolic

diseases, liver and kidney diseases; Chinese Medicine education

ACADEMIC QULIFICATION

BMed, MMed Course (Yunnan TCM, China), PhD (Hokkaido University School of Medicine, Japan)

CURRENT PROFESSIONAL SERVICES

- Panel-member of Chinese medicine for education of Chinese medicine in Hong Kong Chinese Medicine Council;

- Panel-member of Chinese Medicines in Hospital Authority of Hong Kong;

- Panel-member of Chinese Medicine (Pharmaceutical) Committee in Hospital Authority of Hong Kong;

- Panel-member of Use of Proprietary Chinese Medicine Steering Committee in Hospital Authority of Hong Kong;

- Panel-member of Chinese medicine experts for registration of proprietary Chinese medicines in Hong Kong Chinese

Medicine Council;

- Organizing Committee member for International Conference & Exhibition of the Modernization of Chinese

mailto:[email protected]

2

Medicine & Health Products (ICMCM) (Annual Conference, 2005-present);

- Joint-Chairman for International Conference & Exhibition of the Modernization of Chinese Medicine & Health

Products (ICMCM) (2013, 2014, 2018, 2019, Hong Kong);

- Convenor of academic advisory board (2007) and organizing committee for HK-Macao postgraduate Symposium on

Chinese Medicine (Annual Symposium2005-2013, Hong Kong)

- Executive Chairman for The third international symposium and the third national annual conference on dietotherapy

and Chinese medicated diet (2012, Hong Kong)

- External reviewer for Bachelor of Science (Hons) Chinese Medicine Program at International Medical University,

Malaysia (2012-present)

- WHO observer for Regional Launching and Workshop on Implementing the Regional Strategy for Traditional

Medicine in the Western Pacific (2011-2020), 7-8 May 2012, Hong Kong SAR, China

- WHO Expert for The second WHO consultation on quality control of herbal medicines Hong Kong SAR, China, 17-

19 November 2014; 4-6 September 2017

- Organizing committee member for Traditional & Alternative Medicine 2016, Amsterdam, Netherlands, September

14-16, 2016

- Organizing committee Chairman for Pong Ding Yueng International Symposium on Chinese Medicine, Hong Kong,

1-3 December 2017

- Standing member of Hong Kong Registered Chinese Medicine Practitioner Association.

- Editors and reviewers for over seventy international journals in Chinese medicine, integrated medicine,

complementary and alternative medicine, as well as biomedicine etc.

WORK EXPERIENCE

February, 2020 - Present: Acting Director, Associate Professor, Supervisor of PhD Candidates and Post-doctorate

Fellows, School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Hong Kong

Registered Chinese Medicine Practitioner; Master of Chinese Medicine Programme Stream Co-

ordinator (Oncology), School of Chinese Medicine, The University of Hong Kong

Oct. 2017-Nov. 2017: Served as Visiting scientist supported by HKU oversea scholarship in Department of Pharmacology,

Yale University School of Medicine, USA

2014 - 2020: Associate Professor, Associate Director (Education), Supervisor of PhD Candidates and Post-doctorate


Registered Chinese Medicine Practitioner

2011 - 2014: Associate Professor, Assistant Director (Education), Supervisor of PhD Candidates and Post-doctorate



2010 - 2011: Assistant Professor, Assistant Director (Education), Supervisor of PhD Candidates and Post-doctorate



2004 - 2010: Assistant Professor, Bachelor of Chinese Medicine (BChinMed in full- time) Programme Co-Ordinator,

Supervisor of PhD Candidates, School of Chinese Medicine, The University of Hong Kong, Hong Kong;

and Hong Kong Registered Chinese Medicine Practitioner

2002 - 2004: Chinese Medicine Assistant Professor, Supervisor of MPhil candidates, School of Chinese Medicine,

The University of Hong Kong, Hong Kong; and Limited Registered Chinese Medicine Practitioner in

Hong Kong

2000 - 2002: CM Assistant Professor, Division of Chinese Medicine, SPACE, The University of Hong Kong, Hong

3

Kong; and Limited Registered Chinese Medicine Practitioner in Hong Kong.

1997 - 1999: Post-Doctoral research fellow, Department of Laboratory Technology and Department of Medicine II,

Hokkaido University School of Medicine, Japan

1991 - 1993: Visiting Scientist, Department of Pharmacology, Faculty of Pharmacy, Meijio University, Japan

1987 - 1991: Lecturer, Department of Chinese Materia Medica, Yunnan College of Traditional Chinese Medicine,

China

1983 – 1985: Physician, Departments of Infection, Internal Medicine and Chinese Medicine, Dehong People’s

Hospital, Yunnan, China.

RESEARCH INTEREST AND ACHIEVEMENT

Dr Yibin Feng is currently an Associate Professor, Acting Director (Since 6 February 2020) in School of Chinese

Medicine, the University of Hong Kong. Dr. Feng awarded Bachelor degree in Chinese Medicine from Yunnan University

of Chinese medicine in China. He awarded his PhD degree in molecular medicine from Hokkaido University School of

Medicine in Japan. He finished postdoctoral research in molecular pharmacology, Hokkaido University in 1999. In his

early carrier years, Dr. Feng got various scholarships and research funds from Chinese Government, Japanese

Government, Sumitomo social welfare consortium, FUJISAWA Pharmaceutical Limited Incorporation and TSUMURA

KAMPO Pharmaceutical Limited Incorporation etc. His major research areas and research topics are Standardization and

quality control of Chinese Medicines, Pharmacological screening and safety evaluation of Chinese Medicines; and

Pharmacological action and its mechanism of Chinese Medicines as well Chinese medicine education. Recent years, as

a PhD supervisor and principal investigator, his research was supported by grants from the Hong Kong Government

(RGC, ITF, HMRF), donations (such as Pong Ding Yueng Endowment Fund for Education & Research in Chinese-

Western Medicine, Wong’s Donation for molecular cancer research in Chinese medicines, the Gaia Family Trust, Hong

Kong Government-Matching funding), Hong Kong Hospital Authority’s funding for Chinese Medicine, and various

industry contract research funding etc. As PI, awarded various grants over 20 million HK$ from 2004-2020. As Co-I，awarded over 20 million HK$ from 2004-2020.

Being an expert in the study of Chinese Materia Medica, Pharmacology and Toxicology of Chinese medicines, Dr. Feng’s

research is focused on clinical study and experimental study for cancer, diabetes, hepatic and renal diseases by using

recently developed techniques in OMICS, pharmacology and immunology. He also commits to do substitute research for

some endangered species used in Chinese Medicine and Chinese medicine education. He has published over 400

publications in English (118), Japanese and Chinese in these areas. All these publications can be categorized to be top 10

journals and quality one journals in his research field of Chinese medicine, Ethnopharmacology, alternative and

complementary Medicine. His research outputs have great impact on academic field, for example, his paper "Berberine

and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations"

published in Journal of Ethnopharmacology has been ranked No.1 in total 25 of the most cited articles published since

2009 (visiting the Journal web on September 28, 2014), open a new hot topic in the world and make his research always

stand on top level in this field of international arena. His research on coptis and bear bile also got great attention in

academia and society, for example, various media in Hong Kong, Mainland China, Taiwan and Oversea in 2008 have

reported this research, and at an international conference in London in August 2010, he was invited by BBC studio for

interview, he was reported by HKU bulletin in June 2013 about his research story in bear bile and one of his paper

published in Journal of Ethnobiology and Ethnomedicine (Bear bile: dilemma of traditional medicinal use and animal

protection) in 2009 was identified as highly accessed paper over 37000 accesses by March, 2019 on the journal website,

etc.. In addition to publish papers in my research area in journals of Chinese medicine and integrative medicine, I also

published high impact factor papers on Chinese herbal medicine in other reputable journals (Q1 journals in related

categories), such as PLOS ONE (IF4.6), Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (IF5.089),

BBA-Molecular Cell Research (IF 5.297), BBA- Gene Regulatory Mechanisms (IF5.440), Cellular Physiology and

Biochemistry (5.50), Cell death and Disease (IF5.638), BBA - Molecular and Cell Biology of Lipids (IF 5.55), British

journal of Pharmacology (IF6.810), Molecular Cancer (IF10.679), Science Supplement, autophagy (IF11.5), Theranostics

(IF 8.85) and Science Advances (IF 12.8) etc. He has been listed as one of HKU scientists in the world’s Top 1% by

4

Clarivate Analytics (previously Thomason Reuters, Essential Science Indicators) in 2017, 2018 and 2019. He was as lead

guest editor for special issues of liver diseases for academic journals in 2011, 2016 and 2020, such as Chinese Medicine，

Evidence-Based Complementary and Alternative medicine, Frontiers in Pharmacology, etc.

TEACHING SUBJECTS

He has taught subjects such as Chinese Materia Medica, Pharmacology of Chinese Medicines, Toxicology of Chinese

Medicines, Chinese Internal Medicine and Pharmacology. Recently, he is responsible for teaching Chinese Materia

Medica, Pharmacology and toxicology of Chinese medicines, Oncology of Chinese Medicines and research methodology

in Chinese medicine.

CLINICAL SERVICES Cancer, diabetes, obesity, liver diseases and renal diseases etc.

ACADEMIC INTERNATIONAL PROFESSIONAL SERVICE

Highly active in international communities of Chinese Medicine, Ethnopharmacology, complementary and alternative

medicine as well as life science, serving as editors or reviewers for the following international journals:

Editorial Board Members (over ten journals): (1) Evidence-Based Complementary and Alternative Medicine (eCAM)

(2) Integrative Cancer Therapy (3) Chinese Medicine (5) Journal of Bioequivalence & Bioavailability (6) ISRN

Hepatology (7) Open Journal of Apoptosis (8) UC Alternative Medicine (9) International Journal of Cancer & Diagnosis

(IJCRD) (10) Current Analysis in Oncology (11) BMC Complementary Medicine and Therapies, etc.

Reviewers (over sixty journals): Evidence-Based Complementary and Alternative Medicine (IF 2.064), Chinese Journal

of Integrative Medicine (IF 1.059), Journal of Alternative and Complementary Medicine (IF1.464), Molecular and

Cellular Biochemistry (IF3.659), BMC Complementary Medicine and Therapies (IF 2.429), Molecules (IF 3.098), Cell

proliferation (IF 2.521), Journal of Agricultural and Food Chemistry (IF3.412), BioMed Research International (2.88),

Chinese Medicine (IF2.343), Planta Medica (IF 2.339), Free Radical Research (IF3.188), International Journal of

Molecular Sciences (IF4.183), Phytomedicine (IF4.18), Journal of Ethnopharmacology (IF3.414), American Journal of

Chinese Medicine (3.510), Bioorganic & Medicinal Chemistry (IF3.07), Cancer Medicine (IF 3.362), Tumor Biology

(IF3.61), Food and chemical toxicology (IF 3.68), Journal of Ginseng Research (IF 4.082), Oxidative Medicine and

Cellular Longevity (IF 4.936), Molecular oncology (IF 5.350), BSP Current Medicinal Chemistry (CMC, IF4.86), Expert

Opinion On Therapeutic Patents (IF4.297), Expert Opinion on Therapeutic Targets (IF5.139), Science Report (IF 5.578),

BBA-Molecular Cell Research (IF 5.538), Free Radical Biology and Medicine (5.784), Cencers (IF6.102),

Molecular Cancer (IF10.679), Advanced Science (15.804), Nature Metabolism etc..

SELECTED PUBLICATIONS (*CORRESPONDING AUTHOR)

1. Wang N, Tan HY, Li S, Wang D, Xu Y, Zhang C, Wen X, Che CM, Feng Y*. SBP2 Deficiency in

Adipose Tissue Macrophages Drives Insulin Resistance in Obesity. Science Advances 2019 Aug 14;

5(8):eaav0198. doi: 10.1126/sciadv.aav0198. eCollection 2019 Aug. (IF 12.804, 5-year IF13.293)

2. Wang N, Zhu M, Tsao SW, Man K, Zhang ZJ, Feng Y*. MiR-23a-mediated Inhibition of

topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.

Molecular Cancer 2013 Oct 8; 12(1):119. (IF 10.679).

3. Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G, Feng Y*. Fangchinoline induces autophagic

cell death via p53/sestrin2/AMPK signaling in human hepatocellular carcinoma cells. British Journal

of Pharmacology 2011;164(2b):731-742. (IF 6.583, 5-year IF 5.755).

4. Wang N, Tan HY, Li S, Feng Y*. Atg9b Deficiency Suppresses Autophagy and Potentiates

5

Endoplasmic Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis.

Theranostics 2017 Jun 2; 7(8):2325-2338. (IF 8.063, 5-year IF8.651).

5. Tan HY, Wang N, Man K, Tsao SW, Che CM, Feng Y*. Autophagy-induced RelB/p52 activation

mediates tumor associated macrophage repolarisation and suppression of hepatocellular carcinoma

by natural compound baicalin. Cell Death and Disease (2015) 6, e; doi:10.1038/cddis.2015.271 (IF

5.959, 5-year IF 6.211).

6. Tan HY, Ho VWT, Chan YT, Zhang C, Wang N, Xia W, Feng Y*. Combination of Gentiana rhodantha

and Gerbera anandria in the BL02 formula is therapeutic in non-small cell lung cancer acting via

Rap1/cdc42 Signaling: a Transcriptomics/ Bio-informatics biological validation approach.

Pharmacological Research 2019 Aug 26:104415. doi: 10.1016/j.phrs.2019.104415. (IF 5.574, 5-year

IF5.578)

7. Tsang CM, Cheung KCP, Cheung YC, Man K, Lui VWY, Tsao SW, Feng Y*. Berberine suppresses

Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular

carcinoma. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852 (3), 541-551.

(IF 5.108, 5-year IF 5.964).

8. Wang N, Zhang C, Xu Y, Li S, Tan HY, Wang D, Xia W, Feng Y*. OMICs approaches-assisted

identification of macrophages-derived MIP-1γ as the therapeutic target of botanical products TNTL

in diabetic retinopathy. Cell Communication and Signaling 2019 Jul 22;17(1):81. doi:

10.1186/s12964-019-0396-5. (IF 5.111, 5-year IF 4.603)

9. Xu Y, Wang N, Tan Y, Li S, Zhang C, Zhang ZJ, Feng Y*. Notoginseng Saponins-Modulated Gut

Microbiota Regulates Thermogenesis and Browning of White Adipose in Diet-induced Obesity. Gut

Microbes, 2020 accepted for publication. (IF 7.823).

10. Tan HY, Wang N, Chan YD, Zhang C, Guo W, Chen F, Zhong ZF, Li S, Feng Y*. ID1 overexpression

increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent

necroptosis. Cancer Letters, 2020, in press. (IF 6.508, 5-year IF 6.260).

11. Klionsky DJ*,…Feng Y, …et al. Guidelines for the use and interpretation of assays for monitoring

autophagy (3rd edition). Autophagy. 2016 Jan 2; 12(1):1-222. (IF 11.100, and the 5-Year IF is 11.815).

12. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y*. The role of oxidative stress and

antioxidants in liver diseases. International journal of molecular sciences 2015, 16 (11), 26087-26124

(IF 4.181, 5-Year IF 4.331)

13. Tang J, Feng Y*, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis Rhizoma as novel

antineoplastic agents: A review of traditional use and biomedical investigations. Journal of

Ethnopharmacology 2009, 126:5-17. (IF 3.414, 5-year IF 3.671)

14. Wang N, Feng Y*, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell

death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. Journal of cellular

biochemistry 2010, 111(6):1426-36. (IF 3.448, 5-year IF 3.342)

15. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y*. The reactive oxygen species in macrophage

polarization: reflecting its dual role in progression and treatment of human diseases. Oxidative

medicine and cellular longevity 2016, 16pages, https://doi.org/10.1155/2016/2795090. (IF 4.868, 5-

year IF 4.392)

16. Jodo S, Kobayashi S*, Kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H,

Okumura K, Koike T. Serum levels of soluble Fas/APO‐1 (CD95) and its molecular structure in

patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clinical &

Experimental Immunology 1997, 107:89-95. (IF 3.711, 5-year IF 3.516).

17. Feng Y*, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional

medicinal use and animal protection. Journal of Ethnobiology and Ethnomedicine 2009, 5 (1), 2. (IF

https://doi.org/10.1155/2016/2795090

6

2.273, 5-year IF 3.06).

18. Ye XS, Feng Y*, Tong Y, Ng KM, Tsao SW, Lau George KK, Sze CW, Zhang YB, Tang J, Shen JG,

Kobayashi S. Hepatoprotective effects of Coptidis Rhizoma aqueous extract on carbon tetrachloride-

induced acute liver hepatotoxicity in rats. Journal of Ethnopharmacology 2009, 124:130–136. 19. Tsang CM+, Lau Echo PW+, Di K, Cheung PY, Hau PM, Ching YP, Wong YW, Cheung Annie LM, Wan Thomas

SK, Tong Y, Tsao SW* and Feng Y*. Berberine inhibits RhoGTPases and cell migration at low doses but induces

G2 arrest and apoptosis at high doses in human cancer cells. International Journal of Molecular Medicine 2009;

24:131-138. (IF 2.928, 5-year IF 2.843).

20. Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y*. Current status of herbal medicines in chronic liver disease

therapy: the biological effects, molecular targets and future prospects. International journal of molecular sciences

16 (12), 28705-28745. (IF 4.181, 5-Year IF 4.331).

21. Li S, Hong M, Tan HY, Wang N, Feng Y*. Insights into the role and interdependence of oxidative stress and

inflammation in liver diseases. Oxidative medicine and cellular longevity 2016, 2016:4234061. doi:

10.1155/2016/4234061. (IF 4.868, 5-year IF 4.392).

22. Feng Y*, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its

possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic

liver hepatotoxicity in rats. Journal of Ethnopharmacology 2011,138: 683-90 (IF 3.414, 5-year IF

3.671).

23. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-

regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim

Biophys Acta (BBA) - Gene Regulatory Mechanisms. 2014 Sep; 1839(9):849-57 (IF 4.599, 5-year

IF 4.932)

24. Wang N, Feng Y*, Zhu M, Siu FM, Ng KM, Che CM*. A Novel Mechanism of XIAP Degradation

Induced by Timosaponin AIII in Hepatocellular Carcinoma. Biochimica et Biophysica Acta (BBA) -

Molecular Cell Research 2013 Jul 29;1833(12):2890-2899. 1. (IF 4.739, 5-year IF 5.281).

25. Wang N, Feng Y*, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T. Inhibition of Eukaryotic

Elongation Factor-2 Confers to Tumor Suppression by a Herbal Formulation Huanglian-Jiedu

Decoction in Human Hepatocellular Carcinoma. Journal of Ethnopharmacology 2015, 164:309-318

(IF 3.414, 5-year IF 3.671)

26. Xu Q*, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic

botanicals. The Art and Science of Traditional Medicine Part 1: TCM Today – A Case for Integration,

Science 2014;346 (6216 Suppl), S19-S20. 27. Hong M, Wang N, Tan HY, Tsao SW, Feng Y*. MicroRNAs and Chinese medicinal herbs: new possibility in cancer

therapy. Cancers 2015, 7 (3):1643-1657. (IF 6.162).

28. Li S, Wang N, Tan HY, Hong M, Yuen MF, Li H, Feng Y*. Expansion of Granulocytic- Myeloid-

derived Suppressor Cells in Response to Ethanol-Induced Acute Liver Damage. Frontiers in

Immunology. 2018; 9:1524. (IF 4.716, 5-year IF 5.789).

29. Qu Y, Dou B, Tan HY, Feng Y*, Wang N*, Wang D*. Tumor microenvironment-driven non-cell-

autonomous resistance to antineoplastic treatment. Molecular Cancer 2019 Mar 30; 18(1):69. doi:

10.1186/s12943-019-0992-4. (IF10.679)

30. Tan HY, Wang N, Lam W, Guo W, Feng Y*, Cheng YC*. Targeting tumour microenvironment by

tyrosine kinase inhibitor. Molecular Cancer. 2018 Feb 19; 17(1):43. doi: 10.1186/s12943-018-0800-

6. (IF 10.679)

SELECTED BOOKS AND CHAPTERS IN BOOKS (* CORRESPONDING AUTHOR)

1. Xu HX, Zhu GF, Feng Y, Editor-in-Chief. Anticancer Chinese Medicines: Origen, chemistry, pharmacology and

clinical application. Shanghai: Science Publisher. 2018, ISBN 978-7-5478-4080-1/R 1657, pp884. (In Chinese).

2. Chen Chang-xun (Editor in Chief). Editorial board: Cao HY, Chen LY, Chen YF, Fang XY, Feng Y, Gu WL, Gu Y,

7

Hua YQ, Huang LL, Nie Hong, Qu F, Shen YH, Solos L, Wang B, Wang J, Wang N, Wang XB, Wang YY, Xu HB,

Yu S, Zhang JX. Pharmacology of Chinese Materia Medica. National “Thirteenth Five-Year_Plan” Inovative

Textbooks for higher education in Chinese Medicine. China Press of Traditional Chinese Medicine. Beijing. Pp267

(in English).

3. Chen Dexing, Wen xiapin (Editor in Chief), Editorial board: Chen BZ, Chen DX, Du GL, Fan Y, Feng Y, Hu FL,

Hua HM, Jia P, Ni C, Nian L, Ruan SB, Wang F, Wang JN, Wen XP, Xin ZP, Xu XD, Yu Y, Yun XL. National

Textbook for Chinese Medicine Prescription. Qinghua University Press, 1th edition, 2013. Beijing, China. pp394 (in

Chinese).

4. Alan Worsley, Feng Y, Wang N, Ho Faith, Yu Edwin, Rose Mak. Use of Herbs in Chinese and Western Medicine.

Hong Kong Museum of Medical Sciences Society. 1th edition in Bilingual in Chinese and English, 2013. Hong Kong,

China. pp67 (in Bilingual).

5. Xie Mengzhou (Editor in Chief). Editorial board: Shang YQ, Yi W, Zhou J, Wu ZZ, Nie H, Shi LP, Tian SL, Feng Y,

Sun ZM, Li HT, Zhang B, Lin Y, Jin H, Zhou Y, Zhao XW, Guo T, Liang XW, Xie XJ, Tai X, Sun GX. National

Textbook for diet therapy. Zhong Guo Zhong Yi Yao Chu Ban She (China Chinese medicine and Chinese medicines

publisher), 2nd edition, 2013. Beijing, China. pp387. (in Chinese)

6. Feng YG, Wang N, Chueng F, Zhu M, Li H, Feng Y*. Molecular and Cellular Mechanism Studies on Anticancer

Effects of Chinese Medicines. Chapter in Biomedical Engineering, Trends, Research and Technologies (pp332-362).

ISBN 978-953-307-514-3. 2011, pp644. (in English).

7. Feng Y, Chen XM, Wang N and Shen JG*. Current Progress on Medicinal Plants and their Biological Properties in

Contemporary China (Around 20,000 words). Chapter in Recent Progress in Medicinal Plants Vol. 28:

Ethnomedicine: Source & Mechanism-II. Studium Press LLC, USA. 2010, pp491-546. (in English).

8. Tong Y* and Feng Y. Assessments in the Bachelor of Chinese Medicine (BChinMed) Programme. Chapter in The

assessment of the University of Hong Kong. 2009, pp51-58. Published by Institute of Medical and Health Sciences

Education, Li Ka Shing Faculty of Medicine, The University of Hong Kong. (in English).

9. Feng Y*, Editor-in-chief; editorial board: Liu KJ, Wang J, Shen JG, Zhang YB, Rong JH, Tong Y, Chan KS and

Wong Albert B. Basic and Clinical Toxicology of Chinese Medicines (around 460,000 words). Commercial Press

(HK) Ltd. 2009. (Chinese).

10. Yang GQ, Wu ZB, Zhang DN, Jin JM, Feng Y. A study on the prescriptions in “Herbal medicines in Yunnan”.

Published by Science and Technology of Yunnan Press,1993 (ISBN7-5416-0473- 9/R.86).pp.1-319. (in Chinese).

8

馮奕斌博士香港大學中醫藥學院署理院長，副教授

聯絡方法

郵寄地址: 香港薄扶林沙宣道 10號香港大學中醫藥學院

電話: (852) 3917 6476

傳真: (852) 2872 5476

電郵: [email protected]

口頭語言：普通話，英語，廣東話和日語

寫作語言：中文，英文和日文

專業領域：中藥學，中藥藥理學和中藥毒理學；肝腎病學,代謝性疾病和腫瘤學；中醫藥教育

學歷

醫學學士，研究生課程（中國，雲南中醫學院），醫學博士（日本，北海道大學醫學院）.

目前工作簡介

香港大學中醫藥學院副教授，醫學博士, 博士生導師, 長期活耀在中醫藥教育、臨床和研究的第一線，並主管教

學，從學生招生，教材編寫，教學改革，校內外教學評估和教學研究，均發揮領導和主導的作用, 2020 年 2 月

6日起被任命為署理院長。在國內外中醫藥相關的學術領域也發揮著領導作用，如 2012擔任第三屆國際藥膳食

療及第三屆中國藥膳食療大會的大會執行主席，2013，2014 和 2018 年擔任三屆國際現代化中醫藥學術會議聯

席主席(ICMCM)，2017 年香港大學龐鼎元國際中醫藥研討會主席，兼任香港中醫藥管理委員會中醫組中醫學

位課程評審委員，香港醫院管理局中藥委員會委員，香港中醫藥管理委員會中成藥註冊評審專家組專家，香港

註冊中醫學會常務委員，也兼任國內多個大學或研究機構的客座教授，如湖北省楚天講座教授，湖北醫藥學院

神農講座教授，中國科學院和貴州省天然化學重點實驗室教授，國內多個醫藥院校的客座教授等，定期被邀請

作有關領域的學術講座。也曾任日本名城大學，日本北海道大學，沙特國王阿卜杜拉斌健康科學大學和美國耶

魯大學的客座研究員, 客座教授和訪問科學家。近年擔任 60多家國際中醫藥和相關專業雜誌的編委和評審員，

如 BMC Complementary Medicine and Therapies (IF 2.429), Evidence-Based Complementary and Alternative Medicine

(IF 2.064), Integrative Cancer Therapy (IF 2.657), Chinese Medicine (IF2.343) 等的編委, Evidence-Based

Complementary and Alternative Medicine (IF 2.064), Chinese Journal of Integrative Medicine (IF 1.059), Journal of

Alternative and Complementary Medicine (IF1.464), Molecular and Cellular Biochemistry (IF3.659), BMC

Complementary Medicine and Therapies (IF 2.429), Molecules (IF 3.098), Cell proliferation (IF 2.521), Journal of

Agricultural and Food Chemistry (IF3.412), BioMed Research International (2.88), Chinese Medicine (IF2.343), Planta

Medica (IF 2.339), Free Radical Research (IF3.188), International Journal of Molecular Sciences (IF4.183),

Phytomedicine (IF4.18), Journal of Ethnopharmacology (IF3.414), American Journal of Chinese Medicine (3.510),

Bioorganic & Medicinal Chemistry (IF3.07), Cancer Medicine (IF 3.362), Tumor Biology (IF3.61), Food and chemical

toxicology (IF 3.68), Journal of Ginseng Research (IF 4.082), Oxidative Medicine and Cellular Longevity (IF 4.936),

Molecular oncology (IF 5.350), BSP Current Medicinal Chemistry (CMC, IF4.86), Expert Opinion On Therapeutic

Patents (IF4.297), Expert Opinion on Therapeutic Targets (IF5.139), Science Report (IF 5.578), BBA-Molecular Cell

Research (IF 5.538), Free Radical Biology and Medicine (5.784), Cencers (IF6.102), Molecular Cancer (IF10.679),

Advanced Science (15.804), Nature Metabolism etc.的評審員等. 根據 2017，2018, 2019 Clarivate Analytics

(previously Thomason Reuters, Essential Science Indicators)，他被列為香港大學引用率最高的頂尖 1%的學者之一。

mailto:[email protected]

9

工作經歷

2020年 2月 - 至今：香港大學中醫藥學院署理院長，副教授，博士生和博士後導師，香港政府註冊中醫師

香港大學中醫藥學院中醫學碩士腫瘤學統籌

2017 年 10 月-2017年 11月：美國耶魯大學醫學院藥理學系訪問科學家

2014 - 2020：香港大學中醫藥學院副教授，副院長（教學），博士生和博士後導師，香港政府註冊中醫師

2011 - 2014：香港大學中醫藥學院副教授，助理院長（教學），博士生和博士後導師，香港政府註冊中醫師

2010 - 2011：香港大學中醫藥學院助理教授，助理院長（教學），博士生導師，香港政府註冊中醫師

2004 - 2009：香港大學中醫藥學院助理教授，學院全日制課程統籌主任，碩士研究生導師，博士生導師，香港

政府註冊中醫師

2002 - 2004：香港大學中醫藥學院中醫助理教授，碩士研究生導師，香港政府有限度註冊中醫師

2000 - 2002：香港大學專業進修學院中醫助理教授，香港政府有限度註冊中醫師

1997 - 1999：日本札幌市北海道大學醫學院博士後研究學者

1991 - 1993：日本名古屋市名城大學藥學院藥理學訪問科學家

1987 - 1991：中國雲南中醫學院中藥教研室講師

1983 - 1985：中國雲南省德宏州人民醫院醫師

科研方向與業績

專業方向為藥理學，中藥藥理學和中藥毒理學，尤其關注並主要從事中醫藥防治腫瘤和肝腎及糖尿病的

基礎和臨床研究，也專注於所研究領域的保健品、藥物研發以及發酵技術在中藥保健品中的應用，目前指導博

士後 3 名，在讀博士生 6 名，均為高額獎學金獲得者。8 名受訓過的博士、博士後、訪問學者或高級訪問學者

回國後，均獲聘為中國內地著名大學的教授、副教授職位。

馮奕斌博士的研究興趣是中藥在惡性腫瘤，內分泌代謝性疾病和自身免疫性疾病中臨床應用規律的探討；

對中藥單方, 複方及其活性成分的藥理作用, 作用機制和安全性進行評價。研究生涯早期曾獲中國政府，日本政

府，日本北海道政府，北海道大學，日本住友社會福祉財團，日本滕澤製藥股份有限公司和日本津村漢方製藥

有限公司等的獎學金和研究基金。近年獲得香港大學研究基金，香港大學教育發展研究基金，香港政府研究基

金，香港政府創新科技基金，香港政府衛生福利局基金,黃氏基金，龐鼎元中西醫教學與研究基金，大地女神

基金，香港政府配套基金，香港醫院管理局中醫藥研究基金以及香港和內地企業合約研究基金等的支持，作為

首席研究者，獲得超過 2千萬港幣的研究資助，另一方面，結合香港大學多學科及國際網路優勢，作為共同研

究合作者，得到 2千多萬港幣的研究資助，並與英國，美國，加拿大，日本和中國內地形成了廣泛的學術合作。

在多年中西醫結合和應用現代科學技術研究中醫藥的基礎上，建立了肝腎疾病、糖尿病、腫瘤及炎症等技術平

臺，主要應用藥理學，免疫學，細胞分子生物學和組學技術和方法開展對中藥單、複方及有效成分在癌症和肝

腎及糖尿病等方面的基礎和臨床研究。馮奕斌博士的研究團隊會堅持與不同學科的醫生和科學家合作，發揮中

藥多成分，多靶點的特點和優勢，從科學的觀點、臨床醫學和中西醫合作的角度，開展對不同腫瘤的基礎和臨

床研究，重視癌症相關疾病的研究，如代謝性疾病，從癌症患者的實際出發，辨證論治，與西醫藥優勢互補，

並從中醫藥這個偉大寶藏中，為癌症患者及相關疾病患者（糖尿病）提供中醫藥的新療法，新藥物和補充替代

療法。

他的研究團隊學術上的成就，體現在保肝，保腎，降糖，抗炎，抗氧化，細胞死亡，抗腫瘤中藥的物質基

礎和分子作用機制研究，瀕危中藥的替代研究，中醫藥方法學和中醫藥教育研究，主要集中在肝腎疾病病、癌

症和糖尿病的中西醫結合研究上。至 2020 年 1 月, 總的出版物超過 400，在國內外權威學術期刊上發表了學術

論文 151篇（中文 30，英文 116，日文 5），著作 31部（主編中文著作 4，參編英文著作 18，中文著作 7，翻

譯著作 2），獲得或授權中國專利 7項，PCT專利 1項，國內外會議論文或擇要 244篇（中文 47，日文 20，英

文 177），作為大會基調演講，大會演講及國內外特邀講座 100餘次. 馮奕斌博士作為第一作者和通訊作者，衝

擊因數超過 5分的 SCI論文 20餘篇，其他 SCI論文也多排在相關研究領域的前 10位和品質 1類的雜誌 (Journal

of Enthnopharmacology (IF 3.414), American Journal of Chinese Medicine (IF3.58), Biochimica et Biophysica Acta

(BBA) - Molecular Basis of Disease (IF5.089), BBA-Molecular Cell Research (IF 5.297), BBA- Gene Regulatory

Mechanisms (IF5.440), Oncotarget (6.395), Cell death and Disease (IF5.5), BBA - Molecular and Cell Biology of Lipids,

(IF5.55), Cancer (IF6.102), British journal of Pharmacology (IF6.802), Molecular cancer (IF 10.679), Science

10

Supplement, autophagy (IF11.5), Theranostics (IF 8.85), Science Advances (12.8) etc.)，在學術界被高度關注和引用，

如"Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical

investigations"2009年發表在 Journal of Ethnopharmacology, 於 2014年 9月流覽該雜誌時（5年為一個統計節點），

是 2009年以來引用率最高的 25篇論文中被列為第一位，迄今引用率 409次（2019年 8月）在世界上開創了黃

連和黃連素抗惡性腫瘤的熱門話題，他的保肝抗惡性腫瘤的原創性研究也一直站在國際傳統醫藥和民族醫藥學

界研究領域的前沿，而以黃連作為熊膽替代品的研究，在學術和社會上也產生了很大影響，如 2008年 10月被

香港及國內外媒體廣泛報導，2010年 8月在英國參加國際大會時被邀請到 BBC中央演播室接受採訪, 2013年 6

月香港大學公報報導了他研究熊膽替代品及新藥開發的故事，2018年 10月再次接受 BBC採訪，而熊膽替代品

的其中一篇論文發表在 Journal of Ethnobiology and Ethnomedicine，被列為高度關注的論文，迄今被下載流覽了

3.8萬多次（至2019年8月），並為國際雜誌（Chinese Medicine，Evidence-Based Complementary and Alternative

medicine, and Frontiers in Pharmacology）於 2011年, 2016年和 2020年分別主編過三個肝病相關的特別系列。根

據 2017, 2018, 2019 Clarivate Analytics (previously Thomason Reuters, Essential Science Indicators)，他被列為香港

大學引用率最高的頂尖 1%的學者之一（涵蓋過去 10年）。

教學經歷

先後從事過中藥學, 免疫中藥學，中藥藥理學，中藥毒理學, 中醫養生學，中醫腫瘤學，中醫內科學和西藥藥理

學的教學。目前主要擔任臨床中藥學,中藥藥理學和中藥毒理學的教學。

臨床專長

主要從事中醫藥治療內科雜症臨床工作, 長於腫瘤、慢性肝腎疾病、部分內分泌代謝性疾病和自身免疫性疾病

等的診治, 腫瘤如肺癌、鼻咽癌、腸癌、肝癌、胰腺癌、胃癌、食道癌、腦膠質瘤等；其他疾病如代謝綜合症、

牛皮癬、糖尿病、慢性肝炎、慢性腎炎、腎病綜合征等。

主要代表性論著（*通訊作者）

1. Wang N, Tan HY, Li S, Wang D, Xu Y, Zhang C, Wen X, Che CM, Feng Y*. SBP2 Deficiency in

Adipose Tissue Macrophages Drives Insulin Resistance in Obesity. Science Advances 2019 Aug 14;

5(8):eaav0198. doi: 10.1126/sciadv.aav0198. eCollection 2019 Aug. (IF 12.804, 5-year IF13.293)

2. Wang N, Zhu M, Tsao SW, Man K, Zhang ZJ, Feng Y*. MiR-23a-mediated Inhibition of

topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.

Molecular Cancer 2013 Oct 8; 12(1):119. (IF 10.679).

3. Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G, Feng Y*. Fangchinoline induces autophagic

cell death via p53/sestrin2/AMPK signaling in human hepatocellular carcinoma cells. British Journal

of Pharmacology 2011;164(2b):731-742. (IF 6.583, 5-year IF 5.755).

4. Wang N, Tan HY, Li S, Feng Y*. Atg9b Deficiency Suppresses Autophagy and Potentiates

Endoplasmic Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis.

Theranostics 2017 Jun 2; 7(8):2325-2338. (IF 8.063, 5-year IF8.651).

5. Tan HY, Wang N, Man K, Tsao SW, Che CM, Feng Y*. Autophagy-induced RelB/p52 activation

mediates tumor associated macrophage repolarisation and suppression of hepatocellular carcinoma

by natural compound baicalin. Cell Death and Disease (2015) 6, e; doi:10.1038/cddis.2015.271 (IF

5.959, 5-year IF 6.211).

6. Tan HY, Ho VWT, Chan YT, Zhang C, Wang N, Xia W, Feng Y*. Combination of Gentiana rhodantha

and Gerbera anandria in the BL02 formula is therapeutic in non-small cell lung cancer acting via

Rap1/cdc42 Signaling: a Transcriptomics/ Bio-informatics biological validation approach.

Pharmacological Research 2019 Aug 26:104415. doi: 10.1016/j.phrs.2019.104415. (IF 5.574, 5-year

11

IF5.578)

7. Tsang CM, Cheung KCP, Cheung YC, Man K, Lui VWY, Tsao SW, Feng Y*. Berberine suppresses

Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular

carcinoma. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852 (3), 541-551.

(IF 5.108, 5-year IF 5.964).

8. Wang N, Zhang C, Xu Y, Li S, Tan HY, Wang D, Xia W, Feng Y*. OMICs approaches-assisted

identification of macrophages-derived MIP-1γ as the therapeutic target of botanical products TNTL

in diabetic retinopathy. Cell Communication and Signaling 2019 Jul 22;17(1):81. doi:

10.1186/s12964-019-0396-5. (IF 5.111, 5-year IF 4.603)

9. Xu Y, Wang N, Tan Y, Li S, Zhang C, Zhang ZJ, Feng Y*. Notoginseng Saponins-Modulated Gut

Microbiota Regulates Thermogenesis and Browning of White Adipose in Diet-induced Obesity. Gut

Microbes, 2020 accepted for publication. (IF 7.823).

10. Tan HY, Wang N, Chan YD, Zhang C, Guo W, Chen F, Zhong ZF, Li S, Feng Y*. ID1 overexpression

increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent

necroptosis. Cancer Letters, 2020, in press. (IF 6.508, 5-year IF 6.260).

11. Klionsky DJ*,…Feng Y, …et al. Guidelines for the use and interpretation of assays for monitoring

autophagy (3rd edition). Autophagy. 2016 Jan 2; 12(1):1-222. (IF 11.100, and the 5-Year IF is 11.815).

12. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y*. The role of oxidative stress and

antioxidants in liver diseases. International journal of molecular sciences 2015, 16 (11), 26087-26124

(IF 4.181, 5-Year IF 4.331)

13. Tang J, Feng Y*, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis Rhizoma as novel

antineoplastic agents: A review of traditional use and biomedical investigations. Journal of

Ethnopharmacology 2009, 126:5-17. (IF 3.414, 5-year IF 3.671)

14. Wang N, Feng Y*, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell

death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. Journal of cellular

biochemistry 2010, 111(6):1426-36. (IF 3.448, 5-year IF 3.342)

15. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y*. The reactive oxygen species in macrophage

polarization: reflecting its dual role in progression and treatment of human diseases. Oxidative

medicine and cellular longevity 2016, 16pages, https://doi.org/10.1155/2016/2795090. (IF 4.868, 5-

year IF 4.392)

16. Jodo S, Kobayashi S*, Kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H,

Okumura K, Koike T. Serum levels of soluble Fas/APO‐1 (CD95) and its molecular structure in

patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clinical &

Experimental Immunology 1997, 107:89-95. (IF 3.711, 5-year IF 3.516).

17. Feng Y*, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional

medicinal use and animal protection. Journal of Ethnobiology and Ethnomedicine 2009, 5 (1), 2. (IF

2.273, 5-year IF 3.06).

18. Ye XS, Feng Y*, Tong Y, Ng KM, Tsao SW, Lau George KK, Sze CW, Zhang YB, Tang J, Shen JG,

Kobayashi S. Hepatoprotective effects of Coptidis Rhizoma aqueous extract on carbon tetrachloride-

induced acute liver hepatotoxicity in rats. Journal of Ethnopharmacology 2009, 124:130–136. 19. Tsang CM+, Lau Echo PW+, Di K, Cheung PY, Hau PM, Ching YP, Wong YW, Cheung Annie LM, Wan Thomas

SK, Tong Y, Tsao SW* and Feng Y*. Berberine inhibits RhoGTPases and cell migration at low doses but induces

G2 arrest and apoptosis at high doses in human cancer cells. International Journal of Molecular Medicine 2009;

24:131-138. (IF 2.928, 5-year IF 2.843).

20. Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y*. Current status of herbal medicines in chronic liver disease

therapy: the biological effects, molecular targets and future prospects. International journal of molecular sciences

16 (12), 28705-28745. (IF 4.181, 5-Year IF 4.331).

https://doi.org/10.1155/2016/2795090

12

21. Li S, Hong M, Tan HY, Wang N, Feng Y*. Insights into the role and interdependence of oxidative stress and

inflammation in liver diseases. Oxidative medicine and cellular longevity 2016, 2016:4234061. doi:

10.1155/2016/4234061. (IF 4.868, 5-year IF 4.392).

22. Feng Y*, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its

possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic

liver hepatotoxicity in rats. Journal of Ethnopharmacology 2011,138: 683-90 (IF 3.414, 5-year IF

3.671).

23. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-

regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim

Biophys Acta (BBA) - Gene Regulatory Mechanisms. 2014 Sep; 1839(9):849-57 (IF 4.599, 5-year

IF 4.932)

24. Wang N, Feng Y*, Zhu M, Siu FM, Ng KM, Che CM*. A Novel Mechanism of XIAP Degradation

Induced by Timosaponin AIII in Hepatocellular Carcinoma. Biochimica et Biophysica Acta (BBA) -

Molecular Cell Research 2013 Jul 29;1833(12):2890-2899. 1. (IF 4.739, 5-year IF 5.281).

25. Wang N, Feng Y*, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T. Inhibition of Eukaryotic

Elongation Factor-2 Confers to Tumor Suppression by a Herbal Formulation Huanglian-Jiedu

Decoction in Human Hepatocellular Carcinoma. Journal of Ethnopharmacology 2015, 164:309-318

(IF 3.414, 5-year IF 3.671)

26. Xu Q*, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic

botanicals. The Art and Science of Traditional Medicine Part 1: TCM Today – A Case for Integration,

Science 2014;346 (6216 Suppl), S19-S20. 27. Hong M, Wang N, Tan HY, Tsao SW, Feng Y*. MicroRNAs and Chinese medicinal herbs: new possibility in cancer

therapy. Cancers 2015, 7 (3):1643-1657. (IF 6.162).

28. Li S, Wang N, Tan HY, Hong M, Yuen MF, Li H, Feng Y*. Expansion of Granulocytic- Myeloid-

derived Suppressor Cells in Response to Ethanol-Induced Acute Liver Damage. Frontiers in

Immunology. 2018; 9:1524. (IF 4.716, 5-year IF 5.789).

29. Qu Y, Dou B, Tan HY, Feng Y*, Wang N*, Wang D*. Tumor microenvironment-driven non-cell-

autonomous resistance to antineoplastic treatment. Molecular Cancer 2019 Mar 30; 18(1):69. doi:

10.1186/s12943-019-0992-4. (IF10.679)

30. Tan HY, Wang N, Lam W, Guo W, Feng Y*, Cheng YC*. Targeting tumour microenvironment by

tyrosine kinase inhibitor. Molecular Cancer. 2018 Feb 19; 17(1):43. doi: 10.1186/s12943-018-0800-

6. (IF 10.679) 31. 杜永達, 馮奕斌*. 代謝綜合症中醫治療及病案分析一例. 香港中醫雜誌. 2015, 10(2):54-58.

32. 王蕾蕾，王甯，馮奕斌*，張殷建*.中藥治療糖尿病視網膜病變臨床與基礎研究進展.中國中醫眼科雜誌，

2014，24(3): 227-232.

33. 林蓓茵，馮奕斌*. 糖尿病合併結直腸癌關係探討及中藥免煎顆粒治療驗案一例. 香港中醫雜誌. 2014,

9(1):31-36.

34. 陳雷，張凡，馮奕斌*. 中醫藥防治原發性肝癌的臨床研究進展. 香港中醫雜誌 2013, 8(2):80-86.

35. 林蓓茵，馮奕斌*. 糖尿病合併膽管癌關係探討及病案分析一例. 香港中醫雜誌 2013, 8(1):26-29.

36. 林小珊，馮奕斌*. 香砂六君湯合葛根芩連湯治療大腸癌經驗探析.香港中醫雜誌 2011, 6(3):35-38.

37. 林小珊，馮奕斌*. 清熱類中藥抗腫瘤的作用特點及作用機制研究進展.香港中醫雜誌 2009, 4(1):97-105.

38. 馮奕斌*，羅偉權，朱世清. 從黃連及其複方古今臨床應用，發掘現代臨床新應用. 中國中藥雜誌 2008,

33(10):1221-1225. 北京.

39. 馮奕斌*, 童瑤. 從中藥現代研究看中醫學的基本特點. 香港中醫雜誌, 2008; 3 (1): 17-21. 香港.

40. 馮奕斌*，葉星沈，童瑤. 建立香港中藥不良反應監測系統和發揮中醫藥在香港藥物濫用防治中的作用. 中

13

國藥物濫用防治雜誌 2007; 13(4):220-223. 北京.

41. 馮奕斌*，陳抗生. 國內外資料庫中對中藥不良反應和中毒的基本情況及述評.香港中醫雜誌 2007; 2(1):27-

33. 香港.

42. 馮奕斌*, 童瑤, 劉蘋迴.中藥複方研究之探討.香港中醫雜誌，2006;1(2): 64-67. 香港.

43. 馮奕斌, 童瑤, 湯俊，朱世清.試論香港的中藥標準化, 上海中醫藥雜誌 2005; 39(10):3-4. 上海.

44. 馮奕斌*. 中藥學的教學構思和實踐. 中國中醫藥現代遠程教育 2004; 2 (8):38-40. 北京.

45. 馮奕斌*.中藥現代化研究及其展望. 亞太生技 2004;2(1):48-52. 新加坡.

46. 羅偉權, 馮奕斌. 腸瘤消對大腸腺瘤及其癌變患者術後鞏固治療的臨床觀察. 中醫雜誌 2004;45:78-79. 北京.

47. 馮奕斌. 解表祛邪治狐惑. 成都中醫學院學報 1991;14(1):19-20.成都.

48. 馮奕斌. 中藥的現代臨床研究. 雲南中醫學院學報，1987;10(4): 7-10.昆明.

部分代表性書籍 (*主編或通訊作者)

1. 徐宏喜，馮奕斌，朱國福主編，副主編汪選斌，王甯，譚紅勝，張慧卿，郭晨旭，蔡雙璠. 抗腫瘤中藥現

代研究與臨床應用. 上海科技出版社，第一版，2018年 10月，中國上海.

2. 陳長勳主編，編委操紅纓，陳蘭英，陳艷芬，方曉艷，馮奕斌，顧偉梁，顧勇，華永慶，黃莉莉，聶紅，

屈飛，沈雲輝，秦濟成，王斌，王佳，汪寧，汪選斌，王艷艷，徐海波，於爽，張璟璿. 中藥藥理學 (英文

版，全國中醫藥行業高等教育“十三五”創新教材). 中國中醫藥出版社, 第一版，2017. 中國北京. Pp267.

3. 陳德興主編, 文小平, 嚴世芸主審. 編委陳寶忠, 陳德興, 都廣禮, 範穎, 馮奕斌, 胡方林, 華浩明, 賈波, 倪誠, 年

莉, 阮時寶, 王付, 王均甯, 文小平, 辛增平, 徐曉東, 於洋, 雲雪林. 方劑學（普通高等教育“十二五”規劃教材，

全國高等醫藥院校規劃教材）. 清華大學出版社，第一版，2013年 12月，中國北京. pp394.

4. Alan Worsley, Feng Y, Wang N, Ho Faith, Yu Edwin, Rose Mak. Use of Herbs in Chinese and Western Medicine

(天然知源). 香港醫學博物館, 雙語中文版英文版第一版, 2013. 中國香港. pp67.

5. 謝夢洲主編，譚興貴主審，編委：謝夢洲, 尚雲青, 易蔚, 周儉, 吳正治, 聶紅, 史麗萍, 田勝利, 馮奕斌, 孫兆

妹, 李海濤, 張賓, 林雅, 金紅, 周宜, 趙曉薇, 郭彤, 梁曉葳, 謝雪姣, 戴霞, 孫貴香. 中醫藥膳學（全國中醫藥行

業高等教育“十二五”規劃教材，全國高等中醫藥院校規劃教材）. 中國中醫藥出版社, 第二版，2013. 中國

北京. pp387.

6. Feng YG, Wang N, Chueng F, Zhu M, Li H, Feng Y*. Molecular and Cellular Mechanism Studies on Anticancer

Effects of Chinese Medicines. Chapter in Biomedical Engineering, Trends, Research and Technologies (pp331-

362). ISBN 978-953-307-514-3. 2011, pp644. (English).

7. Feng Y, Chen XM, Wang N and Shen JG*. Current Progress on Medicinal Plants and their Biological Properties in

Contemporary China. Chapter in Recent Progress in Medicinal Plants Vol. 28: Ethnomedicine: Source &

Mechanism-II. Studium Press LLC, USA. 2010, pp491-546. (English).

8. Tong Y and Feng Y. Assessments in the Bachelor of Chinese Medicine (BChinMed) Programme. Chapter in The

assessment of the University of Hong Kong. 2009, pp51-58. Published by Institute of Medical and Health Sciences

Education, Li Ka Shing Faculty of Medicine, The University of Hong Kong. (English).

9. 馮奕斌主編，編委劉克儉，王階，沈劍剛，張豔波，容建輝，童瑤，陳抗生，黃伯偉. 基礎和臨床中藥毒

理學. 香港商務印書館, 第一版, 2009. 中國香港. pp394.

10. 楊國祥，吳仲伯, 張大年，金建民，馮奕斌.《滇南本草》附方的研究. 雲南科技出版社，第一版, 1993. 中國

昆明. pp319.

Documents

Dr Feng, Yibin...2020/02/07 · awarded over 20 million HK$ from 2004-2020. Being an expert in the study of Chinese Materia Medica, Pharmacology and Toxicology of Chinese medicines,